Lin BioScience, Inc.

NT$148.00As of Sun 8 Nov 2026, 12:00 UTC
TPEx:6696Healthcare
Country Taiwan
PE (Fwd) •••
TSR 8Y CAGR 57.77%
Div yield —
ROE (21.83%)
Biotechnology
Beta (5Y) —
PE TTM —
TSR TTM 454.31%
Mkt cap NT$122.7B
ROIC (16.00%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$149
0.92%
62.49%
Hold 7|11|5|11|5
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
1.69
1.62
1.75
1.72
11.49%
6.23%
15.16%
12.11%
RevenueNT$B
14.11
13.95
14.51
14.61
10.23%
2.84%
3.10%
3.22%
Peers (US$3.656B)
Cap (US$)
PE
651.0M
354.8x
Capital
TTM
5Y
10Y
Leveragex
0.702
0.034
0.033
EBIT/Intx
2.318
0.181
0.169
Own earn%
(17.32)
88.08
73.17
Sh yield%
43.71
17.17
17.22
Owners
Insiders/Inst%
2.14
72.48
Short interest%
5.30
SBC / revenue%
3.21
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
16
Op margin range%
31–39
$1 testx
0.0
Incr. ROIC%
20